Consequently, ICIs have created a promising clinical scenario for patients with many types of tumors, particularly in patients with tumors that express high PD-L1, or those with elevated tumor-infiltrating immune cells (TILs); this have been demonstrated in different clinical trials that reported significantly better responses to ICIs in patients whose tumors present elevated PD-L1 expression [5–9]. Here, CD274 is linked to neoplasm.